A Look Back at Testing & Diagnostics Services Stocks’ Q2 Earnings: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Pack
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at NeoGenomics (NASDAQ:NEO) and its peers.
The testing and diagnostics services industry plays a crucial role in disease detection, monitoring, and prevention, serving hospitals, clinics, and individual consumers. This sector benefits from stable demand, driven by an aging population, increased prevalence of chronic diseases, and growing awareness of preventive healthcare. Recurring revenue streams come from routine screenings, lab tests, and diagnostic imaging, with reimbursement from Medicare, Medicaid, private insurance, and out-of-pocket payments. However, the industry faces challenges such as pricing pressures, regulatory compliance, and the need for continuous investment in new testing technologies. Looking ahead, industry tailwinds include the expansion of personalized medicine, increased adoption of at-home and rapid diagnostic tests, and advancements in AI-driven diagnostics that enhance accuracy and efficiency. However, headwinds such as reimbursement uncertainties, competition from decentralized testing solutions, and regulatory scrutiny over test validity and cost-effectiveness may impact profitability. Adapting to evolving healthcare models and integrating automation will be key for sustaining growth and maintaining operational efficiency.
The 5 testing & diagnostics services stocks we track reported a very strong Q2. As a group, revenues beat analysts’ consensus estimates by 2.8%.
Thankfully, share prices of the companies have been resilient as they are up 9.4% on average since the latest earnings results.
NeoGenomics (NASDAQ:NEO)
Operating a network of CAP-accredited and CLIA-certified laboratories across the United States and United Kingdom, NeoGenomics (NASDAQ:NEO) provides specialized cancer diagnostic testing services, including genetic analysis, molecular testing, and pathology consultation for oncologists and healthcare providers.
NeoGenomics reported revenues of $201.7 million, up 11.2% year on year. This print exceeded analysts’ expectations by 2.2%. Overall, it was a strong quarter for the company with a beat of analysts’ EPS estimates and a narrow beat of analysts’ full-year EPS guidance estimates.
“Our second quarter results reflect the consistent operating and financial performance investors expect from this team,” said Tony Zook, Chief Executive Officer of NeoGenomics.
Interestingly, the stock is up 30.9% since reporting and currently trades at $17.54.
Is now the time to buy NeoGenomics? Access our full analysis of the earnings results here, it’s free.
Best Q2: RadNet (NASDAQ:RDNT)
With over 350 imaging facilities across seven states and a growing artificial intelligence division, RadNet (NASDAQ:RDNT) operates a network of outpatient diagnostic imaging centers across the United States, offering services like MRI, CT scans, PET scans, mammography, and X-rays.
RadNet reported revenues of $622.7 million, up 25% year on year, outperforming analysts’ expectations by 2.3%. The business had an exceptional quarter with a beat of analysts’ EPS estimates.
The market seems content with the results as the stock is up 1% since reporting. It currently trades at $73.15.
Is now the time to buy RadNet? Access our full analysis of the earnings results here, it’s free.
Weakest Q2: Labcorp (NYSE:LH)
With over 600 million tests performed annually and involvement in 90% of FDA-approved drugs in 2023, Labcorp (NYSE:LH) provides laboratory testing services and drug development solutions to doctors, hospitals, pharmaceutical companies, and patients worldwide.
Labcorp reported revenues of $3.73 billion, up 5.8% year on year, in line with analysts’ expectations. Still, it was a satisfactory quarter as it posted a decent beat of analysts’ full-year EPS guidance estimates.
Labcorp delivered the weakest performance against analyst estimates, slowest revenue growth, and weakest full-year guidance update in the group. The stock is flat since the results and currently trades at $308.72.
Read our full analysis of Labcorp’s results here.
Quest (NYSE:DGX)
Processing approximately one-third of the adult U.S. population's lab tests annually, Quest Diagnostics (NYSE:DGX) provides laboratory testing and diagnostic information services to patients, physicians, hospitals, and other healthcare providers across the United States.
Quest reported revenues of $3.04 billion, up 10.2% year on year. This result topped analysts’ expectations by 2.3%. Overall, it was a very strong quarter as it also produced an impressive beat of analysts’ full-year EPS guidance estimates and a beat of analysts’ EPS estimates.
The stock is up 10.2% since reporting and currently trades at $231.15.
Read our full, actionable report on Quest here, it’s free.
Guardant Health (NASDAQ:GH)
Pioneering the field of "liquid biopsy" with technology that can identify cancer-specific genetic mutations from a simple blood draw, Guardant Health (NASDAQ:GH) develops blood tests that detect and monitor cancer by analyzing tumor DNA in the bloodstream, helping doctors make treatment decisions without invasive biopsies.
Guardant Health reported revenues of $335 million, up 44.3% year on year. This print surpassed analysts’ expectations by 6.4%. Overall, it was a very strong quarter as it also logged full-year revenue guidance exceeding analysts’ expectations.
Guardant Health delivered the biggest analyst estimate beat, fastest revenue growth, and highest full-year guidance raise among its peers. The stock is up 4.2% since reporting and currently trades at $158.78.
Read our full, actionable report on Guardant Health here, it’s free.
Market Update
Over the past year, investors have been forced to repeatedly answer the same question: what is the market’s biggest risk? The answer has changed several times, and each shift has reshaped market leadership.
Late in 2025 and early 2026, artificial intelligence became the market’s primary uncertainty. Investors questioned whether AI would erode software pricing power and weaken competitive moats as AI made it easier to replicate once-differentiated products.
By the spring, technology took a back seat to geopolitics. The U.S. conflict with Iran briefly became the market’s dominant narrative, raising concerns about oil prices, inflation, and global growth. But as energy markets remained orderly and fears of a prolonged supply disruption faded, investors quickly turned their focus back to fundamentals.
Want to invest in winners with rock-solid fundamentals? Check out our Hidden Gem Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.